VictoryShares Small Cap Free Cash Flow ETF(SFLO.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
VictoryShares Small Cap Free Cash Flow ETF
SFLO.US
News
View More

Jazz Pharmaceuticals Showcases Rare Disease Breakthroughs and Growth Strategy in New Presentation

Jazz Pharmaceuticals plc presented at the 44th Annual J.P. Morgan Healthcare Conference, showcasing its achievements and growth strategy in rare disease therapeutics. The company highlighted FDA approval and a successful launch of a drug for extensive-stage small cell lung cancer, generating over $1 billion in sales. It also acquired Modeyso to enhance neuro-oncology expertise and announced a licensing agreement to boost its epilepsy franchise. Positive Phase 3 data for zanidatamab in gastroesophageal adenocarcinoma was emphasized, with a potential market opportunity exceeding $2 billion. The focus remains on rare oncology, epilepsy, and sleep disorders.

Reuters·
US
JAZZ
-1.02%
Reuters·
US
JAZZ
-1.02%

Jazz Pharmaceuticals Completes Acquisition of Chimerix

Jazz Pharmaceuticals has acquired Chimerix, integrating it into its corporate strategy. The acquisition includes the Phase 3 ACTION trial, with Modeyso approval ahead of schedule. Expected revenue for 2025 is nearly $50 million, with further data anticipated by late 2026 or early 2027. The deal may reduce future cash taxes by about $200 million and includes a sale of a Priority Review Voucher for $200 million. The new asset has a peak sales potential exceeding $500 million.

Reuters·
US
JAZZ
-1.02%
Reuters·
US
JAZZ
-1.02%

15:26 ET Stride, Inc. (LRN) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

The Law Offices of Howard G. Smith announced that investors who suffered losses in Stride, Inc. (NYSE: LRN) have the opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that Stride misled investors by inflating enrollment numbers, cutting staffing costs, ignoring compliance requirements, suppressing whistleblowers, and losing student enrollments. Investors must contact the law firm before January 12, 2026, to participate in the lawsuit.

prnewswire·
US
LRN
-0.11%
prnewswire·
US
LRN
-0.11%

Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial

Jazz Pharmaceuticals announced positive Phase 3 trial results for Ziihera (zanidatamab-hrii) in treating advanced HER2-positive stomach cancer. The trial showed that Ziihera, used with chemotherapy, significantly improved progression-free survival (PFS) and overall survival (OS), with median OS exceeding two years, marking a notable advancement in treatment. The data will be presented at the 2026 ASCO Gastrointestinal Cancers Symposium. Jazz's stock rose 2.07% following the announcement.

benzinga_article·
US
JAZZ
-1.02%
benzinga_article·
US
JAZZ
-1.02%

Jazz Pharma Reports Positive Phase 3 HERIZON-GEA-01 Results

Jazz Pharmaceuticals plc (JAZZ) reported positive results from the Phase 3 HERIZON-GEA-01 trial, which evaluated Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra, for treating adults with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. The study demonstrated a significant prolongation of progression-free survival, showing a 35% reduction in the risk of disease progression or death compared to trastuzumab plus chemotherapy.

rttnews·
US
JAZZ
-1.02%
rttnews·
US
JAZZ
-1.02%
© 2026 Longbridge｜Disclaimer